Aminoglycoside-induced ototoxicity

Affiliations

¹ Division of Infectious Diseases (Leis, Gold), Department of Medicine; Centre for Quality Improvement and Patient Safety (Leis); Department of Otolaryngology - Head and Neck Surgery (Rutka), University of Toronto, Toronto, Ont. jerome.leis@sunnybrook.ca.
² Division of Infectious Diseases (Leis, Gold), Department of Medicine; Centre for Quality Improvement and Patient Safety (Leis); Department of Otolaryngology - Head and Neck Surgery (Rutka), University of Toronto, Toronto, Ont.

Review

Jerome A Leis et al. CMAJ. 2015.

. 2015 Jan 6;187(1):E52.

doi: 10.1503/cmaj.140339. Epub 2014 Sep 15.

¹ Division of Infectious Diseases (Leis, Gold), Department of Medicine; Centre for Quality Improvement and Patient Safety (Leis); Department of Otolaryngology - Head and Neck Surgery (Rutka), University of Toronto, Toronto, Ont. jerome.leis@sunnybrook.ca.
² Division of Infectious Diseases (Leis, Gold), Department of Medicine; Centre for Quality Improvement and Patient Safety (Leis); Department of Otolaryngology - Head and Neck Surgery (Rutka), University of Toronto, Toronto, Ont.

No abstract available

References

1. Ariano RE, Zelenitsky SA, Kassum DA. Aminoglycoside-induced vestibular injury: maintaining a sense of balance. Ann Pharmacother 2008;42: 1282–9. - PubMed
1. Black FO, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol 2004; 25:559–69. - PubMed
1. Marais J, Rutka JA. Ototoxicity and topical ear drops. Clin Otolaryngol 1998;23:360–7. - PubMed
1. Zahar JR, Rioux C, Girou E, et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother 2006;58:651–6. - PubMed
1. Berringer R. Aminoglycoside therapy: balancing risk versus benefit [R10814E]. Ottawa: Canadian Medical Protective Association; 2008. Available: https://oplfrpd5.cmpa-acpm.ca/-/aminoglycoside-therapy-balancing-risk-ve... (accessed 2014 Aug. 22).